Description: |
Substantial preclinical antitumor synergy supports the exploration of the combination of antiangiogenic compounds (including bevacizumab) plus ixabepilone. When used as single agents, these compounds have demonstrated substantial activity in renal cell carcinoma. Development of a well-tolerated and active combination of bevacizumab and ixabepilone has the potential to further improve the treatment of metastatic renal cell carcinoma (mRCC), and could represent a second-line option after sunitinib or sorafenib are no longer of benefit or are intolerable. This open label, phase II study has a primary objective of determining the objective response rate of this combination in patients with relapsed or refractory mRCC, as well as progression-free survival, toxicity, and biomarkers. |
Link: |
|
Site: |
NCI |
Principal Investigator: |
Antonio Fojo |